The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Christopher D M Fletcher - One of the best experts on this subject based on the ideXlab platform.
-
cellular angiofibroma a benign neoplasm distinct from angiomyofibroblastoma and spindle cell lipoma
The American Journal of Surgical Pathology, 1997Co-Authors: Marisa R Nucci, Scott R Granter, Christopher D M FletcherAbstract:Four cases of a distinctive Soft-Tissue Tumor of the vulva are described. They were characterized by occurrence in middle-aged women (39-50 years), small size (<3 cm), and a usually well-circumscribed margin. The preoperative clinical diagnosis was that of a labial or Bartholin gland cyst in three
-
the clinical role of molecular genetics in Soft Tissue Tumor pathology
Cancer and Metastasis Reviews, 1997Co-Authors: Klaus J Busam, Christopher D M FletcherAbstract:Cytogenetic and molecular analysis of Soft Tissue Tumors has yielded a wealth of information over the past decade. Some of the genetic aberrations that have been identified appear to be fairly specific for individual Tumor types. It is because of this specificity that these findings harbor the promise to become useful as diagnostic and/or prognostic markers. Technical advances that allow the application of cytogenetic and molecular techniques to archival material have been crucial in this respect.
Akira Kawai - One of the best experts on this subject based on the ideXlab platform.
-
development of nomograms for prognostication of patients with primary Soft Tissue sarcomas of the trunk and extremity report from the bone and Soft Tissue Tumor registry in japan
BMC Cancer, 2019Co-Authors: Masaya Sekimizu, Koichi Ogura, Hideo Yasunaga, Hiroki Matsui, Sakae Tanaka, Katsunori Inagaki, Akira KawaiAbstract:The use of nomograms for prognostication of individual cancer patients has been recommended in order to facilitate precision medicine. However, models for patients with Soft Tissue sarcomas (STSs) are limited because of the rarity and heterogeneity of such cancers. In addition, no model has been developed on the basis of an Asian cohort. Here, we attempted to develop and internally validate nomograms for patients with localized STSs of the trunk and extremity. This study retrospectively extracted 2827 patients with primary trunk and extremity STSs after definitive surgery using the Bone and Soft Tissue Tumor Registry, which is a nationwide sarcoma database in Japan. We developed three nomograms predicting the probability of local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and disease-specific survival (DSS) at 2 years after surgery, using the Cox multivariate model. The nomograms were internally validated for discrimination and calibration using bootstrap resampling and assessed for their clinical applicability by decision curve analysis (DCA). Local recurrence, distant metastasis and disease-specific death occurred in 241 patients (8.5%), 554 patients (19.6%) and 230 patients (8.1%), respectively. Histological diagnosis, grade and Tumor size strongly influenced all three endpoints. The nomograms predicted accurately the probability of LRFS, DMFS and DSS (concordance index: 0.73, 0.70 and 0.75, respectively). DCA demonstrated that our nomograms had clinical applicability. We have developed the first nomograms for STSs based on an Asian cohort. These nomograms allowed accurate prediction of LRFS, DMFS and DSS at 2 years after definitive surgery, and can be used as a guide by clinicians for appropriate follow-up and counseling of patients.
-
clinical features and treatment outcome of desmoid type fibromatosis based on a bone and Soft Tissue Tumor registry in japan
International Journal of Clinical Oncology, 2019Co-Authors: Yoshihiro Nishida, Keisuke Ae, Tomoya Matsunobu, Junya Toguchida, Toshiyuki Kunisada, Yoshihiro Matsumoto, Akira Ogose, Kunihiko Takahashi, Akira Kawai, Kazuki NishidaAbstract:Treatment modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative treatment. In this study, Tumor characteristics of DF, transition of the treatment modality, and clinical outcome of surgical treatment were analyzed based on data obtained from the bone and Soft Tissue Tumor registry established in Japan. Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical treatment. The number of registered patients increased gradually. The frequency of surgical treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with Tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin (P = 0.34). The treatment modality has shifted from surgical to conservative treatment, with risk factors for surgical treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.
-
clinical outcome of primary giant cell Tumor of bone after curettage with or without perioperative denosumab in japan from a questionnaire for jcog 1610 study
World Journal of Surgical Oncology, 2018Co-Authors: Hiroshi Urakawa, Yoshihiro Matsumoto, Seiichi Matsumoto, Tatsuya Takagi, Tsukasa Yonemoto, Kunihiro Asanuma, Munenori Watanuki, Akira Takemoto, Norifumi Naka, Akira KawaiAbstract:Background Giant cell Tumor of bone (GCTB) is an intermediate Tumor known to be locally aggressive, but rarely metastasizing. To plan a prospective study of GCTB, we performed a questionnaire survey for institutions participating in the Bone and Soft Tissue Tumor Study Group (BSTTSG) in the Japan Clinical Oncology Group (JCOG) in 2015.
-
statistics of bone sarcoma in japan report from the bone and Soft Tissue Tumor registry in japan
Journal of Orthopaedic Science, 2017Co-Authors: Koichi Ogura, Takahiro Higashi, Akira KawaiAbstract:Abstract Background No previous reports to date have characterized the national profiles of Soft-Tissue sarcomas (STSs). In the present study, we reviewed current practice for STSs in Japan using data from a nationwide organ-specific cancer registry for bone and Soft-Tissue Tumors in Japan, the Bone and Soft Tissue Tumor (BSTT) Registry. Methods In the registry, we identified 8228 patients with STSs during the period 2006–2012, and extracted data on patient demographics, treatment, and outcome at the last follow-up for each patient. Disease-specific survival was analyzed using the Cox proportional hazards model. Results STSs showed a slight male predilection. The age distribution had a single peak in the seventh decade, the proportion of elderly patients aged >60 years being approximately 53%. For most of the histologic subtypes, the most frequent Tumor location was the lower extremity, whereas it was the trunk in patients with malignant peripheral nerve sheath Tumor, dedifferentiated liposarcoma, and primitive neuroectodermal Tumor. Based on data for 2432 patients with STSs, we found significant associations between disease-specific survival and age, sex, histologic subtype, Tumor size, Tumor depth, Tumor location, additional surgery, limb salvage status, and surgical margin; elderly patients showed the poorest disease-specific survival. Conclusions Using the BSTT Registry, this study has clarified the epidemiology, treatment, and prognosis of patients with STSs in Japan. Our experiences with the BSTT Registry will be of help to other countries where aging of the population is occurring. Continuous accumulation of clinical data in the BSTT Registry should provide more informative data on STSs, thus improving both the level of medical care offered by clinicians and the outcomes for patients through sharing of such data and promotion of clinical research.
Shinichiro Ushigome - One of the best experts on this subject based on the ideXlab platform.
-
collagenous fibroma desmoplastic fibroblastoma a distinctive fibroblastic Soft Tissue Tumor
Advances in Anatomic Pathology, 1999Co-Authors: Masaharu Fukunaga, Shinichiro UshigomeAbstract:Collagenous fibroma is a distinct, benign, fibroblastic/myofibroblastic proliferation, probably neoplasm. It is a slow-growing Tumor arising in predominantly subcutaneous Tissue. This Tumor is composed of stellate-shaped fibroblasts and abundant interstitial collagen. Since none of reported collagenous fibromas recurred, simple excision is an appropriate treatment. Collagenous fibroma should be differentiated from fibromatosis, which has a high risk of local recurrence if simple local excision is done. Fibromatosis is more cellular and shows short fascicular arrangements of Tumor cells and greater infiltration at the periphery than collagenous fibroma.
Ting Shen - One of the best experts on this subject based on the ideXlab platform.
-
fine needle aspiration cytology of intra abdominal wall extraskeletal myxoid chondrosarcoma a case report and review of the literature
Archives of Pathology & Laboratory Medicine, 2003Co-Authors: Farah Gaudier, Jasvir S Khurana, Sanjiv Dewan, Ting ShenAbstract:Abstract Extraskeletal myxoid chondrosarcoma is a rare Soft Tissue Tumor. Most of the reported cases that were diagnosed by fine-needle aspiration were taken from the extremities, where the Tumor is often found. Problems can occur when the site is unusual and cellular differentiation is not distinct. We present a case in which the Tumor was located in the intra-abdominal wall, an unusual location. Cytologic features and immunocytochemistry are helpful in distinguishing this Tumor from others that share similar myxoid background.
Marilyn M Bui - One of the best experts on this subject based on the ideXlab platform.
-
Soft Tissue Tumor immunohistochemistry update illustrative examples of diagnostic pearls to avoid pitfalls
Archives of Pathology & Laboratory Medicine, 2017Co-Authors: Shi Wei, Evita Hendersonjackson, Xiaohua Qian, Marilyn M BuiAbstract:Context.— Current 2013 World Health Organization classification of Tumors of Soft Tissue arranges these Tumors into 12 groups according to their histogenesis. Tumor behavior is classified as benign...
-
molecular pathology of Soft Tissue neoplasms and its role in clinical practice
Cancer Control, 2015Co-Authors: Evita Hendersonjackson, Marilyn M BuiAbstract:Background: Soft-Tissue neoplasms embody a histologically diverse group of mesenchymal Tumors. Oftentimes the histopathological diagnosis of Soft-Tissue Tumors is challenging due to overlapping pathological features. Methods: We reviewed the current and most importantly known recurrent or Tumor-specific genetic abnormalities involving Soft-Tissue Tumors, focusing on how they are useful in working up differential diagnoses and the relevance of potentially targeted therapies. Results: Molecular diagnostic tools have shown great advantage as an aid in the differentiation between different Soft-Tissue Tumor entities, providing a potential avenue in the identification of novel therapeutic targets. Gastrointestinal stromal Tumor is a well-known example of a Soft-Tissue Tumor with a successful, molecularly driven treatment with response rates of more than 80% in stable disease and partial remission. Classifying Soft-Tissue neoplasms by their molecular genetic pathology has been considered as molecular testing becomes more integrated into various diagnostic and prognostic algorithms. Conclusions: Molecular pathology provides a unique opportunity for pathologists to play a crucial role in the multidisciplinary care of patients with sarcoma. These opportunities include but are not limited to the appropriate triage of Tissue for molecular testing and the integration of molecular testing results, with histological and immunohistochemical findings providing actionable information for the diagnosis, prognosis, and choice of therapeutic modality.
